This company listing is no longer active
71M Stock Overview
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Myovant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €25.19 |
| 52 Week High | €27.11 |
| 52 Week Low | €7.29 |
| Beta | 2.15 |
| 1 Month Change | 1.90% |
| 3 Month Change | 0.32% |
| 1 Year Change | 137.87% |
| 3 Year Change | 319.83% |
| 5 Year Change | 70.90% |
| Change since IPO | 129.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 71M | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | -4.3% | -2.5% |
| 1Y | 137.9% | -19.4% | -0.4% |
Return vs Industry: 71M exceeded the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: 71M exceeded the German Market which returned -5.6% over the past year.
Price Volatility
| 71M volatility | |
|---|---|
| 71M Average Weekly Movement | 1.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 71M has not had significant price volatility in the past 3 months.
Volatility Over Time: 71M's weekly volatility has decreased from 11% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 579 | Dave Marek | myovant.com |
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction.
Myovant Sciences Ltd. Fundamentals Summary
| 71M fundamental statistics | |
|---|---|
| Market cap | €2.62b |
| Earnings (TTM) | -€172.71m |
| Revenue (TTM) | €356.29m |
6.9x
P/S Ratio-14.2x
P/E RatioIs 71M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 71M income statement (TTM) | |
|---|---|
| Revenue | US$379.11m |
| Cost of Revenue | US$209.66m |
| Gross Profit | US$169.45m |
| Other Expenses | US$353.22m |
| Earnings | -US$183.77m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.89 |
| Gross Margin | 44.70% |
| Net Profit Margin | -48.47% |
| Debt/Equity Ratio | -64.3% |
How did 71M perform over the long term?
See historical performance and comparison